Compare AFYA & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AFYA | SDGR |
|---|---|---|
| Founded | 1999 | 1990 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2019 | 2020 |
| Metric | AFYA | SDGR |
|---|---|---|
| Price | $13.49 | $30.70 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $17.00 | ★ $21.00 |
| AVG Volume (30 Days) | 253.4K | ★ 1.7M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.90% | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $255,869,000.00 |
| Revenue This Year | $10.43 | $0.76 |
| Revenue Next Year | $7.15 | $4.60 |
| P/E Ratio | $9.30 | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $13.00 | $10.95 |
| 52 Week High | $16.41 | $31.03 |
| Indicator | AFYA | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 42.92 | 79.21 |
| Support Level | $13.38 | $11.27 |
| Resistance Level | $14.84 | N/A |
| Average True Range (ATR) | 0.41 | 1.78 |
| MACD | -0.07 | 1.08 |
| Stochastic Oscillator | 16.90 | 96.33 |
Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergraduate, deriving key revenue provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex-health undergraduate programs, Continuing Education provides medical education, specialization and graduate courses in medicine, delivered through digital and in-person content; and Medical practice solution provides clinical decision, clinical management and doctor-patient relationships for physicians and provide access, demand and efficiency for the healthcare players.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.